Moses Technology vs Vapor Tunnel in Low Power Laser Lithotripsy (MT VT)

November 10, 2026 updated by: Polyvios Arseniou, National and Kapodistrian University of Athens

Double Blind Randomized Controlled Trial Comparing Two Distinct Pulse Modulation Modes in Low Power Laser Lithotripsy

The goal of this clinical study is to compare two different laser settings used to break up kidney and ureter stones during surgery. The study will include adults with kidney or ureter stones who are scheduled to undergo a procedure in which an endoscope is passed through the urinary tract and a laser is used to break the stones into smaller pieces.

The main question is whether one laser setting can break up stones using less energy than the other, while maintaining similar treatment effectiveness and safety.

A total of 110 participants will be randomly assigned to one of two groups:

  • One group will undergo stone treatment using Moses Technology.
  • The other group will undergo stone treatment using Vapor Tunnel.

Both methods use a laser to break stones into smaller pieces. The study will compare the amount of laser energy used in relation to the size of the stone. Researchers will also assess the duration of the procedure, how completely the stones are cleared, the movement of stones during surgery, and any complications.

The findings may help urologists understand which laser setting is more efficient and whether it offers advantages during the treatment of kidney and ureter stones.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

110

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Attica
      • Marousi, Attica, Greece, 15126
        • 2nd Department of Urology, Sismanogleio General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • kidney/ureter stone
  • maximum stone diameter 5-20 mm (CT)
  • any stone composition
  • recent CT (3 months prior to procedure)
  • indication/no contraindications for laser lithotripsy
  • negative urine culture/adequate antibiotic preparation
  • informed consent

Exclusion Criteria:

  • pregnancy
  • inability/unwillingness to provide informed consent
  • radiolucent stones
  • ipsilateral urinary tract anatomical abnormalities
  • previous non-endoscopic surgery on the urinary tract
  • active urinary tract infection
  • acute kidney injury
  • bleeding disorders
  • inability to discontinue antithrombotic medication when required for the procedure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Moses Technology

Laser lithotripsy using Moses Technology pulse modulation by Lumenis Pulse 120H Ho:YAG laser system, that produces a two-part laser pulse. The first low-energy part produces a vapor cavity through which the second high-energy part is transmitted to the stone without energy loss, increasing laser efficacy.

Other Names:
  • Ho:YAG Laser Lithotripsy
Active Comparator: Vapor Tunnel

Laser lithotripsy using Vapor Tunnel pulse modulation by Quanta Cyber Ho Ho:YAG laser system, which creates one low-power long-length laser pulse that prevents stone retropulsion.

Other Names:
  • Ho:YAG Laser Lithotripsy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Laser efficacy
Time Frame: During ureteroscopic procedure

Total energy delivered by the Ho:YAG laser during stone lithotripsy, divided by the preoperative stone volume measured on computed tomography (CT). The result will be expressed in joules per cubic millimeter (J/mm³).

During ureteroscopic procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Laser-on time
Time Frame: During ureteroscopic procedure

The cumulative duration of laser activation during stone lithotripsy, measured in minutes and recorded by the laser system.

During ureteroscopic procedure
Operative time
Time Frame: During ureteroscopic procedure

The total duration of the ureteroscopic procedure, measured in minutes from the beginning to the completion of the surgical procedure.

During ureteroscopic procedure
Total energy
Time Frame: During ureteroscopic procedure

The cumulative energy delivered by the Ho:YAG laser during stone lithotripsy, measured in joules (J) and recorded by the laser system.

During ureteroscopic procedure
Lithotripsy rate
Time Frame: During ureteroscopic procedure

Lithotripsy rate calculated as the preoperative stone volume, measured on CT in cubic millimeters, divided by the total laser activation time in seconds. Results will be expressed in mm³/s.

During ureteroscopic procedure
Stone-free rate
Time Frame: One month after ureteral stent removal (ureteral stent removal typically removed 7-10 days after discharge)

The proportion of patients with no residual stone fragments larger than 3 mm on postoperative computed tomography (CT).

One month after ureteral stent removal (ureteral stent removal typically removed 7-10 days after discharge)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intraoperative complications
Time Frame: During ureteroscopic procedure

The proportion of patients experiencing one or more complications during the ureteroscopic procedure, including their type and nature.

During ureteroscopic procedure
Postoperative complications
Time Frame: Within 30 days after the ureteroscopic procedure

The proportion of patients experiencing postoperative complications, including their type and severity, classified according to the Clavien-Dindo classification system.

Within 30 days after the ureteroscopic procedure
Length of hospital stay
Time Frame: From hospital admission until discharge

The duration of hospitalization, calculated as the number of days from hospital admission to hospital discharge.

From hospital admission until discharge
Stone retropulsion
Time Frame: During ureteroscopic procedure

Surgeon-assessed stone retropulsion during laser lithotripsy, evaluated according to the distance of stone displacement, frequency of retropulsion events, and impact of retropulsion on the completion of stone fragmentation.

During ureteroscopic procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

October 1, 2029

Study Registration Dates

First Submitted

November 3, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 88866-24/7/2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.